Yue Zhao

10PUBLICATIONS
16CO-AUTHORS
Toxicology (incl. clinical toxicology)Cancer therapy (excl. chemotherapy and radiation therapy)PharmacogenomicsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Adolescent health
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Sep 24, 2025
Model-Informed Drug Development of Subcutaneous Nivolumab: Comparison of Pharmacokinetic Analysis Methodologies Using Clinical Trial Simulation.

Yue Zhao, Heather Vezina, Zheyi Hu

|Jul 26, 2024
Model-based population pharmacokinetic and exposure response analyses for safety and efficacy of nivolumab as adjuvant treatment in subjects with resected oesophageal or gastroesophageal junction cancer.

Yue Zhao, Akihide Tsujimoto, Takafumi Ide

|Jan 31, 2024
Model-Informed Clinical Pharmacology Profile of a Novel Fixed-Dose Combination of Nivolumab and Relatlimab in Adult and Adolescent Patients with Solid Tumors.

Yue Zhao, Zheyi Hu, Sai Praneeth Bathena

|Dec 20, 2023
Nivolumab and ipilimumab population pharmacokinetics in support of pediatric dose recommendations-Going beyond the body-size effect.

Zheyi Hu, Sihang Liu, Yue Zhao

|Dec 20, 2023
Model-Based Dose Selection of Subcutaneous Nivolumab in Patients with Advanced Solid Tumors.

Yue Zhao, Kinjal Sanghavi, Amit Roy

|Oct 24, 2023
Pediatric model-based dose optimization using a pooled exposure-response safety analysis for nivolumab and nivolumab plus ipilimumab combination in melanoma.

Shengnan Du, Yue Zhao, Zheyi Hu

Pageof 2

Frequent Collaborators

5 joint publications

Amit Roy

2 joint publications

Huidong Gu

1 joint publications

Naiyu Zheng

1 joint publications

Michael D Reily